Skip to main content

The context you need, when you need it

When news breaks, you need to understand what actually matters — and what to do about it. At Vox, our mission to help you make sense of the world has never been more vital. But we can’t do it on our own.

We rely on readers like you to fund our journalism. Will you support our work and become a Vox Member today?

Join now

Lexmark to Buy Kofax for $1 Billion to Boost Software Business

Kofax provides data services to financial, insurance and health care companies.

Lexmark

Lexmark International, known for its printers, said it would buy Kofax for about $1 billion in a deal that would double the size of its enterprise software business.

Kofax shares were up 45.5 percent at $10.91 in extended trading on Tuesday, just shy of Lexmark’s $11 per share cash offer. Lexmark shares rose 8 percent.

PC and printer makers have struggled in the recent past as companies reduced printing to cut costs and consumers shifted to mobile devices from PCs.

Hewlett-Packard plans to separate its computer and printer businesses from its corporate hardware and services operations this year.

Xerox has also increasingly focused on IT services to make up for the falling sales of its copiers and printers.

Lexmark divested its inkjet printer business in 2013 and has since boosted its enterprise software business.

The Kofax deal will help the company’s Perceptive Software business achieve its revenue target of $500 million in 2016, Lexmark said.

The business makes software to scan everything from spreadsheets to medical images and provides services to banking, health care, insurance and retail companies. It contributed about 8 percent to Lexmark’s revenue in 2014 and has grown at more than 30 percent in the past two years.

Kofax provides data services to financial, insurance and health care companies such as Citigroup, Metlife and Humana.

Lexmark said it expects the deal to “significantly” expand operating margins in its enterprise software business, which would now be worth about $700 million. It will also add about 10 cents per share to the company’s adjusted profit in 2015.

Lexington, Kentucky-based Lexmark, which expects to close the deal in the second quarter, said it would suspend share repurchases until it pays off its short-term debt in 18-24 months.

Goldman Sachs is the financial adviser to Lexmark, while Lazard is the financial adviser to Kofax.

Lexmark reported $3.7 billion in adjusted revenue in 2014.

Kofax, headquartered in Irvine, California, reported $297 million in adjusted revenue in the year ended June 2014.

(Reporting by Anya George Tharakan and Devika Krishna Kumar in Bengaluru; Editing by Joyjeet Das)

This article originally appeared on Recode.net.

See More:

More in Technology

Podcasts
Are humanoid robots all hype?Are humanoid robots all hype?
Podcast
Podcasts

AI is making them better — but they’re not going to be doing your chores anytime soon.

By Avishay Artsy and Sean Rameswaram
Future Perfect
The old tech that could help stop the next airborne pandemicThe old tech that could help stop the next airborne pandemic
Future Perfect

Glycol vapors, explained.

By Shayna Korol
Future Perfect
Elon Musk could lose his case against OpenAI — and still get what he wantsElon Musk could lose his case against OpenAI — and still get what he wants
Future Perfect

It’s not about who wins. It’s about the dirty laundry you air along the way.

By Sara Herschander
Life
Why banning kids from AI isn’t the answerWhy banning kids from AI isn’t the answer
Life

What kids really need in the age of artificial intelligence.

By Anna North
Culture
Anthropic owes authors $1.5B for pirating work — but the claims process is a Kafkaesque messAnthropic owes authors $1.5B for pirating work — but the claims process is a Kafkaesque mess
Culture

“Your AI monster ate all our work. Now you’re trying to pay us off with this piece of garbage that doesn’t work.”

By Constance Grady
Future Perfect
Some deaf children are hearing again because of a new gene therapySome deaf children are hearing again because of a new gene therapy
Future Perfect

A medical field that almost died is quietly fixing one disease at a time.

By Bryan Walsh